Whales with a lot of money to spend have taken a noticeably bullish stance on Lockheed Martin. Looking at options history for Lockheed Martin LMT we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Starbucks. Looking at options history for Starbucks SBUX we detected 27 trades. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and ...

Investors with a lot of money to spend have taken a bullish stance on IonQ IONQ. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Agios' ACTIVATE-Kids trial showed 31.6% of mitapivat-treated children met the hemoglobin response endpoint vs. 0% in the placebo group. Agios reported Q4 Pyrukynd revenue of $10.7M, exceeding the $9.33M consensus, with 130 patients on therapy and cash reserves of $1.5B.

NEW YORK, Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ( "Neumora Therapeutics, Inc." or the "Company" ) NMRA of a class action securities lawsuit.

TAP posts better-than-expected results in fourth-quarter 2024. Financial volumes fall 6.4% year over year, mainly led by lower shipments.

AI agents can now coach you through your video games, thanks to the Balance.fun companion platform and its soon-to-launch Ethereum token.

NEW YORK, Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ( "Novo" or the "Company" ) NVO of a class action securities lawsuit.

VinFast delivered 53,139 EVs in Q4, a 342% increase YoY, reaching a total of 97,399 EVs for the full year, exceeding targets. VinFast plans to double its global deliveries in 2025. Get real-time earnings alerts before the market moves and access expert analysis that uncovers hidden opportunities ...

West Pharmaceutical's Q4 adjusted EPS was $1.82, surpassing the $1.72 consensus, while revenue hit $748.8M, beating estimates of $740.47M. The company forecasts 2025 adjusted EPS of $6.00-$6.20, missing the $7.44 consensus, with revenue guidance of $2.875B-$2.91B below estimates